Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ETR028 and ETR029 in Healthy Adults
NCT05572190Phase 1Recruiting
- Sponsor
- Elysium Therapeutics
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ETR029 in acute pain (17 arms), sponsored by Elysium Therapeutics. Primary endpoints: Pharmacokinetic profile, Adverse Events and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
ETR029
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05572190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572190.